SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3D rendering of a T-cell
Approvals
Adaptimmune’s Tecelra Becomes First FDA-Approved Engineered Cell Therapy for Solid Tumors
Approved under the regulator’s accelerated pathway, Tecelra is also the first new synovial sarcoma therapy in more than a decade, according to Adaptimmune Therapeutics.
August 2, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's office in Dresden, Germany
Approvals
GSK Wins Broad Label Expansion for Jemperli in First-Line Endometrial Cancer
In pursuit of Merck’s blockbuster Keytruda, GSK’s Jemperli scored its own broad FDA label expansion, allowing its use in first-line endometrial cancer regardless of biomarker status.
August 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Business people holding a meeting in a conference room
Earnings
Vir Lays Off 25% of Staff, Abandons Most Virus Work and Pivots to Cancer in Sanofi Deal
As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.
August 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Vertex Pharmaceuticals' headquarters in Boston, Massachusetts
Pipeline
Vertex Scraps Two Phase I AATD Candidates Following Disappointing Data
Poor efficacy data for two early-stage candidates for the rare disease alpha-1 antitrypsin deficiency have convinced Vertex Pharmaceuticals to terminate their development.
August 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Earnings
Moderna Cuts Full-Year Revenue Guidance as COVID-19 Vaccine Sales Crater in Q2
Moderna’s stock price plunged more than 20% in Thursday morning trading after the company lowered its 2024 revenue guidance due to weak demand for its coronavirus vaccine in the second quarter.
August 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Handshake in front of raining money / Ta
Deals
Otsuka Pays Up to $1.1B to Buy Jnana, Adds Drug Discovery Capabilities
With an upfront $800 million payment and $325 million in potential milestones, Otsuka Pharmaceutical is acquiring Jnana Therapeutics’ drug discovery platform and rare disease candidate, the companies announced Thursday.
August 1, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Lilly's Institute for Genetic Medicine building in Boston
Cardiovascular disease
Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo
Eli Lilly on Thursday released late-stage data showing a 38% reduction in the risk of heart failure outcomes, as it plays catch-up with Novo Nordisk’s semaglutide which won the FDA’s cardio nod in March.
August 1, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Adcomms
FDA Questions Strength of Evidence Backing Zevra’s Rare Disease Therapy Ahead of Adcomm
The Genetic Metabolic Diseases Advisory Committee will meet on Friday to discuss Zevra’s modified scale to describe the efficacy of its drug candidate for the treatment of Niemann-Pick disease type C.
August 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk's corporate headquarters in Denmark
IRA
Novo Loses IRA Case as NJ Judge Asserts Price Negotiations Are Voluntary
Reiterating his ruling in a prior Inflation Reduction Act case, New Jersey District Court Judge Zahid Quraishi ruled that Novo Nordisk’s participation in the Medicare Drug Price Negotiation Program is of its own free will.
August 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS